Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
-
BUSINESS Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
-
COMMENTARY Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
-
BUSINESS Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
-
BUSINESS Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
-
BUSINESS Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
-
BUSINESS Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
-
BUSINESS SSP to Roll Out Pharmacist Training Ahead of OTC Cialis Launch in Japan
October 1, 2025
-
ORGANIZATION Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
-
BUSINESS Heartseed, Novo Nordisk End Global Cell Therapy Pact
October 1, 2025
-
BUSINESS Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
-
BUSINESS Parexel Exec Says FDA Keeps Reviews on Track amid Staff Cuts, but Notes Leadership Drain
September 30, 2025
-
COMMENTARY FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
-
BUSINESS Industry Fears Trump’s MFN Drug Pricing Push Could Deepen Japan’s Lag and Loss
September 29, 2025
-
REGULATORY Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
REGULATORY Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
-
REGULATORY Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
-
BUSINESS Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
-
BUSINESS Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
-
REGULATORY FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…